



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48	A1	(11) International Publication Number: WO 97/18839 (43) International Publication Date: 29 May 1997 (29.05.97)
(21) International Application Number: PCT/EP96/05118 (22) International Filing Date: 20 November 1996 (20.11.96) (30) Priority Data: 95203219.1 23 November 1995 (23.11.95) EP (34) Countries for which the regional or international application was filed: AT et al. (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): BAERT, Lieven, Elvire, Colette [BE/BE]; Gouden Boomstraat 52/3, B-8000 Brugge (BE). PEETERS, Jozef [BE/BE]; Sint Corneliusstraat 64, B-2430 Beerse (BE). VERRECK, Geert [BE/BE]; Salvialaan 5, B-2980 Zoersel (BE). (74) Agent: DE CORTE, Filip; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).		(81) Designated States: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: SOLID MIXTURES OF CYCLODEXTRINS PREPARED VIA MELT-EXTRUSION (57) Abstract Process for preparing a solid mixture comprising one or more cyclodextrins and an insoluble active ingredient characterized in that said process comprises a melt-extrusion step, wherein the active ingredient is embedded into the cyclodextrin carrier.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

SOLID MIXTURES OF CYCLODEXTRINS PREPARED VIA MELT-EXTRUSION

- 5 The present invention involves a process for preparing solid mixtures by melt-extrusion comprising one or more active ingredients, preferably one or more practically insoluble active ingredients and one or more cyclodextrins. The invention further concerns pharmaceutical compositions comprising the above mixture.
- 10 WO 94/11031, published on May 5, 1994, discloses a method of manufacturing a high-quality enclosure compound using extrusion techniques. In this document the extrusion of cyclodextrins together with an active ingredient is mentioned. However, the document discloses the use of a wet mixture (i.e. including water or another solvent) to feed into the extruder.
- 15 French patent application 2,705,677 published on December 2, 1994 describes microgranules obtained by extrusion-spheronisation containing a cyclodextrin. The extrusion-spheronisation technique is the combination of an agglomeration technique, i.e. extrusion, and a shaping technique, i.e. the spheronisation. Said patent application
- 20 actually teaches the formation of microgranulates containing β -cyclodextrin (Kleptose®) and microcrystalline cellulose (Avicel®) and as active ingredients ketoprofen and paracetamol. The extrusion technique used in the above-mentioned patent application consists in preforming a humid mass by forcing said human mass through a nozzle thus forming long strands of extruded material. The document does
- 25 not mention melt-extrusion at all.
- EP 0,665,009, published as international application on April 24, 1994, discloses a method of dislocating the crystalline condition of crystalline medicine by extruding said crystalline material as such, i.e. without any excipient such as cyclodextrins.
- 30 In J. Pharm. Pharmacolog., vol 44, No 2, pages 73-8, Uekama *et al* show how amorphous nifedipine powders were prepared by spray-drying with hydroxypropyl- β -cyclodextrins. The document does not mention melt-extrusion.
- 35 In Pharm. Weekbl. Sci. Ed., 1988, vol 10, No 2, page(s) 80-85, Van Doorne *et al*, the complex formation between β -cyclodextrins and six antimicrobial imidazole derivatives was studied. In said study gels and creams comprising antimicrobials were prepared

whereby a 1.8 % solution of β -cyclodextrin was added instead of purified water. There is no mentioning of extrusion at all.

5 In J. Antimicrob. Chemother., 1993, vol 32, No 3, pages 459-463, Hostetler *et al* describe the effect of hydroxypropyl- β -cyclodextrin on the efficacy of oral itraconazole in disseminated murine cryptococcosis. In said document the authors describe how itraconazole is solubilized in hydroxypropyl- β -cyclodextrin resulting in a 100 ml solution. There is no mentioning at all of an extrusion process.

10 In Jpn. J. Med. Mycol., 1994, vol 35, No 3, page 263-267, Mikami *et al* describe the effect of carrier solvents on the efficacy of oral itraconazole therapy in aspergilosis in mice. Again this document discloses itraconazole being solubilized in hydroxypropyl- β -cyclodextrin. There is no mentioning of extrusion techniques.

15 In "Effect of 2-Hydroxypropyl- β -cyclodextrin on Crystallization and Polymorphic Transition of Nifedipine in Solid State", Pharmaceutical research, vol 11, No 12, 1994, Uekama *et al.* describe a glassy mixture of 2-hydroxypropyl- β -cyclodextrin obtained by heating said mixture and immediately cooling said mixture to 0 degrees Celsius. There is no teaching that this mixture can be extruded.

20 US 5,009,900 describe glassy matrices that are useful for introducing and/or retaining and/or stabilizing the volatile and/or labile components in cooked and uncooked food products. These glassy matrices comprise chemically modified starch having a dextrose equivalent not greater than about 2; maltodextrin, corn syrup solids or a
25 polydextrose, and a mono- or disaccharide. The document does disclose extrusion to form glassy matrices. However, there is no specific mentioning of cyclodextrins and of therapeutically or pharmaceutically active ingredients.

None of the above mentioned documents disclose the present invention.

30 Although WO 94/11031 and French patent application 2,705,677 disclose extrusion of mixtures of cyclodextrins and actives ingredients, said documents do not mention the use of meltextrusion. The technique described in WO 94/11031 and French patent application 2,705,677 has a main disadvantage, that a humid mass needs to be prepared
35 which requires adding to the cyclodextrin and the active ingredient a certain amount of water and in most cases others solvents such as ethanol or methanol. Removing the water and/or other solvents is often a troublesome production step, which often leads to

irreproducibility because not all of the solvent can be removed. Moreover, with practically insoluble active ingredients the amounts of water and/or adjuvant solvents needed make the above technique unpractical on a production scale. Another disadvantage of the technique described in the prior art is that the drying step can induce unwanted crystallization of the active ingredient.

These problems are solved in the present invention by the use of a melt-extrusion process to form solid mixtures comprising one or more cyclodextrins and insoluble active ingredients.

The present process is advantageously applicable when said active ingredient is sensitive to a solvent such as water or an organic solvent, because it does not require any solvent. The term "sensitive" used herein means that the active ingredient is readily (e.g. within about one hour) influenced by a solvent to such an extent that its physical, chemical and/or biological properties are substantially modified or changed.

The present process is further advantageous because it does not require a drying step, during which insoluble active ingredients often tend to crystallize.

The term "insoluble" hereinabove and hereinunder refers to three categories of compounds, i.e. the "very slightly soluble", "practically insoluble" and "insoluble".

The terms "very slightly soluble", "practically insoluble" or "insoluble" are to be understood as defined in the United States Pharmacopeia 23, NF 18 (1995) page 7, i.e. a "very slightly soluble" compound requires from 1000 to 10,000 parts of solvent for 1 part of solute; a "practically insoluble" or "insoluble" compound requires more than 10,000 parts of solvent for 1 part of solute. The solute referred to in these cases are water or aqueous solutions.

Three examples of this type of insoluble compounds are : itraconazole, loviride and (\pm)-ethyl (R*,R*)-4-[5-[1-[1-[(4-chlorophenyl)hydroxymethyl]propyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-2-pyridinyl]-1-piperazinecarboxylate (hereinafter referred to as compound 1).

Itraconazole is an art-known antifungal. Loviride is an art-known anti-retrovirally active compound, particularly useful in treating HIV-infected patients.

(±)-Ethyl (R*,R*)-4-[5-[1-[1-[(4-chlorophenyl)hydroxymethyl]propyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-2-pyridinyl]-1-piperazinecarboxylate is described as compound No. 3, in WO 95/27704 published on October 19, 1995.

- 5 The compounds that are suitable to be used in this technique are compounds that show no appreciable decomposition at the temperatures needed to melt and extrude the mixture of said one or more active ingredients with the cyclodextrin or cyclodextrins.

The term "active ingredient" further refers to compounds or mixtures of compounds
10 which are pharmaceutically or therapeutically or cosmetically active for treating humans or animals.

The present invention provides a process for preparing a solid mixture comprising one or more cyclodextrins and an (insoluble) active ingredient, comprising a melt-extrusion
15 step wherein one or more cyclodextrins are combined with the one or more active ingredients.

Melt-extrusion is a polymer extrusion technique which involves embedding an active ingredient in one or more carriers. In this technique the active ingredient and
20 excipients are molten in the extruder and hence embedded in thermoplastic and thermomelting polymers. The resulting molten mass is then forced through one or more nozzles resulting in a thermoplastic strand or strands.

An extruder comprises an inlet structure, a cylindrical structure called "barrel", a die
25 and a screw or screws. A schematic overview is shown in Figure 1.

The inlet structure mostly is funnel shaped.

The barrel may comprise one or more barrel units and the screw or screws extend
30 through them.

Extruders are available in two general types, namely a single-screw extruder comprising one screw and a multi-screw extruder comprising two or more screws. While this invention can be carried out using either type of extruder, the use of a multi-
35 screw extruder, particularly a twin-screw extruder is preferred. A twin-screw extruder (and a multi-screw extruder) is more efficient in that the plural screws interfering with

each other precludes follow-up movement of the active ingredient and, moreover, the intermeshing of the screws provides a high energy output physically.

An interesting mode of operating the screws is to operate them in a corotating mode.

5

The screw or screws may have different shapes such as, for example, a trapezoidal screw, a trapezoidal cut screw, trapezoidal reverse cut screw, ball screw, kneading paddle and these may be used in the desired combination.

10 The load fed into the extruder via the inlet structure is forced by the screw or screws to advance, shorn and blended by the screw within the barrel and extruded from the orifice or orifices of the die. The temperature of the barrel or of the barrel units can be controlled via a heating element or even if necessary by a cooling element.

15 The rotational speed of the screw can be set within the allowable range of the extruder used.

A person skilled in the art is able to select the screw geometry and combination of unit screws. The principal function of the screw is to transport, crush and knead the
20 material that is being extruded.

The orifice configuration may be circular, elliptical, rectangular or hexagonal.

Hence, said melt-extrusion step comprises the following substeps :

- 25 a) mixing one or more cyclodextrins with the active ingredient or active ingredients,
b) optionally mixing additives,
c) heating the thus obtained mixture until melting of one of the components,
d) forcing the thus obtained mixture through one or more nozzles;
e) cooling the mixture till it solidifies.

30

If desired, as mentioned above, the thermomelting mixture comprising one or more cyclodextrins and active ingredient(s) may comprise any suitable additive. When, for instance, the cyclodextrin(s) or the active ingredient(s) or one of the other possible additives is apt to be oxidized, an anti-oxidizing agent may be incorporated, preferably
35 in small amounts, such as, for instance 100 to 5000 ppm when compared to the total weight of the mixture. Furthermore, conventional auxiliary additives such as pigments, flavors, stabilizers, preservatives and buffers may be added.

If necessary conventional pharmacologically acceptable plasticizers, such as long chain alcohols, ethylene glycol, propylene glycol, triethylene glycol, butanediols, pentanols, hexanols, polyethylene glycols, aromatic carboxylates (e.g. dialkyl phthalates, trimellitates, benzoates or terephthalates), aliphatic dicarboxylates or fatty acid esters can also be added. Preferably however, a plasticizer is not needed.

The term "melting" should be broadly interpreted. "Melting" can also refer to the fact that some transition is made to a glassy state, in which it is possible for one component of the mixture to get embedded into the other. In particular cases, one component will melt and the other component(s) will dissolve in the melt thus forming solid solutions, which show advantageous dissolution properties.

The possible formation of these solid solutions is one of the further advantages of the present invention. It will be appreciated by a person skilled in the art that mixing two or more solids, i.e. one or more cyclodextrins and the active ingredient or ingredients, and subsequently melting these solids together will give rise to different products than when the said solids are first brought into contact with water or another solvent and then extruded.

A characteristic of the melt extruded mixtures of the present invention is the fact that they contain substantially less water or any other solvent than mixtures being extruded in an other way.

Preferably the present melt extruded mixtures contain no water or solvent, apart from the water or solvent that eventually is contained in the crystal structure of the active ingredient.

It will be appreciated that the temperature inside the extruder is an important parameter. When different barrel units are present, different temperatures can be applied. A person skilled in the art is able to establish the required temperatures by taking the desired type of cyclodextrin or cyclodextrins or even the complete mixture that is going to be extruded and observing the behaviour as a function of temperature with the aid of a melting point measuring instrument, such as a Kofler hot bench, a microscope hot stage type or a differential scanning calorimeter, e.g. type DSC 7 Series - Perkin Elmer.

The cooling can be performed without using any auxiliary means, i.e. it most often suffices to let the thermoplastic strand coming out of the extruder cool down to the ambient temperature of the production site. Of course, cooling aids may be used.

- 5 Once these thermoplastic strands are cooled down these strands can be milled to obtain a powdered form of the mixture of cyclodextrin or cyclodextrins and the active ingredient.

- 10 A person skilled in the art will appreciate that the milling can influence the physical characteristics of the extrudate. During milling the temperature of the material can rise because of the friction and also high shear forces are exerted on the material that is to be milled. Both temperature and mechanical or shear forces can result in a transition of the physical state of the material that is to be milled. A person skilled in the art has sufficient means at his disposal to control temperature and shear forces and thus to
15 control the milling process.

- The two processes, i.e. melt extrusion and milling can be combined into one configuration as is shown in Figure 1. The mixture of one or more cyclodextrins and one or more active ingredients in combination with possible other additives is feed via
20 a funnel like inlet. The mixture is then melt-extruded and the mixture is forced through a nozzle onto a conveyor belt. While being transported on the conveyor belt the extrudate cools down. The cooled melt extrudate is fed into a chopper which forms pellets. These pellets may be further milled if required.

- 25 This powdered material still has the beneficial properties (high bioavailability, dissolution rate, etc.) and it can be used in the conventional way to prepare pharmaceutical, therapeutical or cosmetical solid dosage forms.

- 30 An additional advantage of the present invention is that the active ingredient as well as the cyclodextrins may be transformed in a amorphous form or even that a solid solution is formed. A person skilled in the art will appreciate that this modification of physical state from crystalline to amorphous or to solid solutions is highly advantageous for the dissolution.

- 35 The fact whether the melt extruded mixture contains amorphous material or contains a solid solution or consists essentially of amorphous material or a solid solution can be measured or checked using differential scanning calorimetry. When there is crystalline

material present in the melt extruded mixture a differential scanning calorimeter will show an endothermic melting peak. When amorphous material or a solid solution is mainly present in the melt extruded mixture a differential scanning calorimeter will not show an endothermic melting peak. Visual inspection of the melt extrudate allows for a distinction between amorphous material and a solid solution. In case the melt extrudate is opaque then both the cyclodextrin(s) and the active ingredient are in a amorphous form. In case melt extrudate is clear then a solid solution was formed.

Curves of differential scanning calorimetry are shown in Figures 2 to 7.

Interesting embodiments of the present invention are these melt extruded mixtures which consist mainly of amorphous material.

More interesting embodiments of the present invention are these melt extruded mixtures which consist essentially of amorphous material.

Even more interesting embodiments of the present invention are those melt extruded mixtures which consist mainly of a solid solution of the active ingredient or active ingredients in the cyclodextrin or the cyclodextrins.

Preferred embodiments of the present invention are those melt extruded mixtures which consist essentially of a solid solution of the active ingredient or active ingredients in the cyclodextrin or the cyclodextrins.

Another advantage of the present invention is that the granulation step in forming pharmaceutical, therapeutical or cosmetical compositions can be omitted, because the powdered material can simply be mixed with other excipients and compressed into, for instance, tablets or another solid pharmaceutical, therapeutical or cosmetical form.

Depending upon the characteristics of the melt extruded mixture, the size of the pellets of said melt extruded mixture or the mesh of the powder of said melt extruded mixture and, of course, dependent upon the other auxiliaries that are added to the unit dosage forms the unit dosage form may give immediate release or sustained release.

If desired, said solid pharmaceutical form may also be provided with a conventional coating to improve the appearance and/or the flavor (coated tablets) or additionally to target the release of the active ingredient.

Suitable tablets may have the following compositions and may be prepared in a conventional way. The amounts given are of course dependent upon the dose required for the pharmaceutical, therapeutic or cosmetic activity.

5

Composition A

	milled melt extrudate	100 - 500 mg
	microcrystalline cellulose	100 - 300 mg
10	crospovidone	10 - 200 mg
	colloidal silicon dioxide	1 - 5 mg
	sterotex	2 - 10 mg

15

Composition B

	milled melt extrudate	100 - 500 mg
	Microcelac (TM) (1)	200 - 300 mg
	crospovidone	70 - 200 mg
	talc	20 - 50 mg
20	sterotex	7 - 10 mg
	colloidal silicon dioxide	1 - 5 mg
	magnesium stearate	2 - 10 mg

25 The cyclodextrin to be used in the aforementioned compositions include the pharmaceutically acceptable unsubstituted and substituted cyclodextrins known in the art, more particularly α , β or γ cyclodextrins or the pharmaceutically acceptable derivatives thereof.

30 Substituted cyclodextrins which can be used in the invention include polyethers described in U.S. Patent 3,459,731. In general, unsubstituted cyclodextrins are reacted with an alkylene oxide, preferably under superatmospheric pressure and at an elevated temperature, in the presence of an alkaline catalyst.

35 Since a hydroxy moiety of the cyclodextrin can be substituted by an alkylene oxide which itself can react with yet another molecule of alkylene oxide, the average molar substitution (MS) is used as a measure of the average number of moles of the substituting agent per glucose unit. The MS can be greater than 3 and theoretically has no limit.

Further substituted cyclodextrins are ethers wherein the hydrogen of one or more cyclodextrin hydroxy groups is replaced by C₁₋₆alkyl, hydroxyC₁₋₆alkyl, carboxy-C₁₋₆alkyl or C₁₋₆alkyloxycarbonylC₁₋₆alkyl or mixed ethers thereof. In particular such substituted cyclodextrins are ethers wherein the hydrogen of one or more
5 cyclodextrin hydroxy groups is replaced by C₁₋₃alkyl, hydroxyC₂₋₄alkyl or carboxyC₁₋₂alkyl or more in particular by methyl, ethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, carboxy-methyl or carboxyethyl.

In the foregoing definitions the term "C₁₋₆alkyl" is meant to include straight and
10 branched saturated hydrocarbon radicals, having from 1 to 6 carbon atoms, such as, methyl, ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, 2-methylpropyl, butyl, pentyl, hexyl and the like.

Such ethers can be prepared by reacting the starting cyclodextrin with an appropriate
15 O-alkylating agent or a mixture of such agents in a concentration being selected so that the desired cyclodextrin ether is obtained. The said reaction is preferably conducted in a suitable solvent in the presence of an appropriate base. With such ethers, the degree of substitution (DS) is the average number of substituted hydroxy functions per glucose unit, the DS being thus 3 or less.

20 In the cyclodextrin derivatives for use in the compositions according to the present invention, the DS preferably is in the range of 0.125 to 3, in particular 0.3 to 2, more in particular 0.3 to 1 and the MS is in the range of 0.125 to 10, in particular of 0.3 to 3 and more in particular 0.3 to 1.5.

25 Of particular utility in the invention are the β -cyclodextrin ethers, e.g. dimethyl- β -cyclodextrin as described in Drugs of the Future, Vol. 9, No. 8, p. 577-578 by M. Nogradi (1984) and polyethers, e.g. hydroxypropyl β -cyclodextrin and hydroxyethyl β -cyclodextrin, being examples. Such an alkyl ether may be a methyl ether with a degree
30 of substitution of about 0.125 to 3, e.g. about 0.3 to 2. Such a hydroxypropyl cyclodextrin may for example be formed from the reaction between β -cyclodextrin and propylene oxide and may have a MS value of about 0.125 to 10, e.g. about 0.3 to 3.

A more novel type of substituted cyclodextrins is sulfobutylcyclodextrines. These type
35 are also envisaged in the present invention.

The ratio of active ingredient over cyclodextrin may vary widely. For example ratios of 1/100 to 100/1 may be applied. Interesting ratios of active ingredient over cyclodextrin range from about 1/10 to 10/1. More interesting ratios of active ingredient over cyclodextrin range from about 1/5 to 5/1. Most interesting ratios range from about 1/3 to 3/1. Preferred ratio is about 1/1.

The use of a mixture of cyclodextrins, either different types (α , β , γ) or different substitution (2-hydropropyl or methyl) or different substitution grades is sometimes recommendable to decrease the melting point.

Description of the drawings

Figure 1 is a schematic representation of a configuration for carrying out the present invention.

Figure 2 is a differential scanning calorimetry curve (DSC curve) of non-milled Batch No 1 material. (see Example 1)

Figure 3 is a differential scanning calorimetry curve of milled Batch No 1 material (see Example 1)

Figure 4 is a differential scanning calorimetry curve of Batch No 2 material (see Example 1)

Figure 5 is a differential scanning calorimetry curve of Batch No 3 material (see Example 1)

Figure 6 is a differential scanning calorimetry curve of Batch No 4 material (see Example 1)

Figure 7 is a differential scanning calorimetry curve of Batch No 5 material (see Example 1)

Example 1

Extruded samples of active ingredient with hydroxypropyl- β -cyclodextrin (HP- β -CD) were obtained using a Twin Screw Extruder type MP19 APV Baker (commercially available from the company APV Baker) with a die having an orifice of 3 mm. The process parameters for each individual experiment are shown in the table 1. This type of extruder has a L/D ratio of 15 and a screw pattern : 4D FS - 4x30 FP - 4x60 FP - 4x90 P - 4x60 RP - 2.5D FS - 2x30 FP - 2x60 FP - 2x90 P - 3x60 RP - 3 DFS. (4D refers to a transport element having a length of 4 times the screw diameter of the feed screw type; 4x30 FP refers to 4 forward paddles positioned with mutual angle of 30

degrees, 4x60 RP refers to a working zone having reverse paddles positioned with a mutual angle of 60 degrees)

5 In this type of extruder the mixture is fed by a feeding screw turning a constant feeding speed (v1) (A feeding speed of 10 revolutions per minute amounts to a feeding speed of 1,5 kg per hour) onto the twin transporter screws having a diameter of 18 mm turning at a transporter speed (v2). These speeds are rotational speeds (revolutions per minute).

10 The mixture is then transported into a first heating zone (t1). Here the rate of transport diminished by a difference of the configuration of the twin transporter screws i.e. the rotational transporter speed v2 remains the same but the material does not progress as quickly.

15 Subsequently, the molten mass is transported by again normal configuration twin transporter screws to a second heating zone (t2) where the rate of transport is again diminished by a difference of configuration of the twin transporter screws.

20 After this second heating the thermomelting mixture is transported to the nozzle of the apparatus.

Table 1

mixture	Batch. No	t ₁ (°C)	t ₂ (°C)	t _p (°C)	v ₁ (rpm)*	v ₂ (rpm)*
$\frac{\text{compound 1}}{\text{HP-}\beta\text{-CD}} : \frac{1}{3}$	1	256	283	280	10	100
$\frac{\text{itraconazole}}{\text{HP-}\beta\text{-CD}} : \frac{1}{1}$	2	263	265	279	10	20
$\frac{\text{itraconazole}}{\text{HP-}\beta\text{-CD}} : \frac{1}{3}$	3	264	265	280	10	20
$\frac{\text{loviride}}{\text{HP-}\beta\text{-CD}} : \frac{1}{1}$	4	274	285	292	10	80
$\frac{\text{loviride}}{\text{HP-}\beta\text{-CD}} : \frac{1}{3}$	5	258	265	274	10	20

25 * rpm = revolutions per minute

- t₁ : temperature of the first heating zone
- t₂ : temperature of the second heating zone

- t_p : temperature inside the barrel
- v_1 : rate of feeding screw
- v_2 : twin transporter screws speed(rotational).

5 In every case the mixture of active ingredient and 2-hydroxypropyl- β -CD gave a solid solution.

Example 2

10 Extruded samples of active ingredient with dimethyl- β -cyclodextrin (DM- β -CD) were obtained using extruder type MP19 - APV Baker with the process parameters as shown in the table 2.

15 Table 2

mixture	Batch. No.	t_1 (°C)	t_2 (°C)	t_p (°C)	v_1 (1) (rpm)*	v_2 (rpm)*
$\frac{\text{compound 1}}{\text{DM-}\beta\text{-CD}} : \frac{1}{1}$	6	241	245	254	0	20
$\frac{\text{itraconazole}}{\text{DM-}\beta\text{-CD}} : \frac{1}{1}$	7	239	240	253	0	20
$\frac{\text{loviride}}{\text{DM-}\beta\text{-CD}} : \frac{1}{1}$	8	248	250	263	0	20

* rpm = revolutions per minute

(1) The apparatus was fed manually, without using the feeding screw.
In every case the mixture of active ingredient and DM- β -CD.

- 20
- t_1 : temperature of the first heating zone
 - t_2 : temperature of the second heating zone
 - t_p : temperature inside the barrel
 - v_1 : feeding screw speed (rotational)
 - v_2 : twin transporter screw speed (rotational).

25

Example 3

The dissolution of the melt extrudate of Batch No 1 was compared with the dissolution of the "physical mixture" (i.e. the mixture of the two component in the ratio as shown for Batch No. 1, but not melt extruded).

30

An amount of 100 mg of milled melt extrudate of Batch No 1 was added to a volume of 900 ml of artificial gastric juice at a temperature of 37 degrees Celsius. The stirring method used was the peddle method with a peddle moving at 100 rotations per minute. Using UV spectrometry the relative amount of dissolved extrudate was measured during 1 hour.

The same procedure for the "physical mixture" was followed.

The results of this dissolution process are shown in Table 3

Table 3

time mixture (minutes)	milled extrudate Batch No 1 (% of total amount dissolved)	corresponding physical (% of total amount dissolved)
0	0.00	0.00
5	62.10	1.71
15	70.20	14.67
30	72.63	21.06
45	74.07	26.10
60	74.25	28.35

Example 4

The melting behaviour was measured by using differential scanning calorimetry. The calorimeter used is the Perkin-Elmer 7 Series Thermal Analysis System. In all cases the rate of heating was set at 20 degrees Celsius per minute.

Figure 2 shows the DSC curve of melt extrudate of Batch No 1 before milling. The curve shows no endothermic or exothermic peaks and it was established by visual inspection that the molten material was a clear solution, thus indicating that the non-milled melt extrudate of Batch No 1 is a solid solution.

Figure 3 shows the DSC curve of melt extrudate of Batch No 1 after milling. The curve shows no endothermic or exothermic peaks and it was established by visual inspection that the molten material was a clear solution, thus indicating that the milled melt extrudate of Batch No 1 is a solid solution.

Figure 4 shows the DSC curve of meltextrudate of Batch No 2 before milling. The curve shows no endothermic or exothermic peaks and it was established by visual inspection that the molten material was not a clear solution, thus indicating that the non-milled melt extrudate of Batch No 2 is a mixture of amorphous material.

5

Figure 5 shows the DSC curve of meltextrudate of Batch No 3 before milling. The curve shows a small endothermic peak. The data on said small peak are as follows :
X1 = 117.600 degrees Celsius, X2 = 143.200 degrees Celsius, Peak at 132.695 degrees Celsius, Area is 38.126 mJ, ΔH is 3.768 J/g, Height is 1.520 mW and the onset is at
10 125.816 degrees Celsius. Said small peak is very probably due to an impurity in the cyclodextrins. It was established that the non-milled melt extrudate of Batch No 3 is a mixture of amorphous material.

15

Figure 6 shows the DSC curve of meltextrudate of Batch No 4 before milling. The curve shows a few small endothermic peaks. Hence, it was established that the non-milled melt extrudate of Batch No 4 is a mixture of amorphous material containing small amounts of crystalline material

20

Figure 7 shows the DSC curve of meltextrudate of Batch No 5 before milling. The curve shows no endothermic or exothermic peaks and it was established by visual inspection that the molten material was not a clear solution, thus indicating that the non-milled melt extrudate of Batch No 5 is a mixture of amorphous material.

Example 5

25

The melt extrudate of Batch No. 1 was milled and sieved. By mixing the appropriate amounts a tablet having the following composition was prepared in an art-known way :

30

milled extrudate batch No 1	480 mg
microcrystalline cellulose	218 mg
Aerosil	3 mg
magnesium stearate	5 mg
crospovidone	144 mg

Claims

1. Process for preparing a solid mixture comprising one or more cyclodextrins and one or more active ingredients characterized in that said process encompasses a melt-extrusion step, wherein the active ingredient is embedded into the cyclodextrin carrier.
5
2. A process as claimed in claim 1, wherein the melt-extrusion process comprises the following substeps :
10
 - a) mixing one or more cyclodextrins with one or more active ingredients, and
 - b) optionally mixing additives;
 - c) heating the thus obtained mixture until melting of one of the components;
 - d) forcing the thus obtained mixture through one or more nozzles;
 - 15 e) cooling the mixture till it solidifies.
3. A solid mixture obtainable by the process as described in any of claims 1 or 2, with the proviso that nifedipine in combination with 2-hydroxypropyl- β -cyclodextrin is excluded.
20
4. A solid mixture as claimed in claim 3 characterized in that the active ingredient or active ingredients are insoluble according to the definition of US Pharmacopeia.
5. A solid mixture as claimed in claims 3 or 4, wherein substantially only one type of cyclodextrin is present.
25
6. A solid mixture as claimed in any of claims 3 to 5 wherein a cyclodextrin is hydroxypropyl- β -cyclodextrin.
- 30 7. A solid mixture as claimed in any of claim 3 to 5 wherein a cyclodextrin is dimethyl- β -cyclodextrin.
8. A solid mixture as claimed in any of claims 3 to 7, wherein the active ingredient is itraconazole.
35
9. A solid mixture as claimed in any of claims 3 to 7 wherein the active ingredient is loviride.

10. A solid mixture as claimed in any of claims 3 to 7 wherein the active ingredient is (\pm)-ethyl (R*,R*)-4-[5-[1-[1-[(4-chlorophenyl)hydroxymethyl]propyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-2-pyridinyl]-1-piperazinecarboxylate.
- 5 11. A pharmaceutical composition comprising milled melt extrudate and other excipients.
- 10 12. A process for preparing a pharmaceutical composition as claimed in claim 11 characterized by milling appropriately the solid mixture as claimed in any of claims 4 to 10, intimately mixing the thus obtained powdered material with other pharmaceutically acceptable excipients and further processing into pharmaceutical dosage forms.




Fig. 2




Fig. 3




Fig. 4




Fig. 5






Fig. 6



7/7

Fig. 7



A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 11031 A (NIPPON SHINYAKU CO LTD) 26 May 1994 cited in the application see abstract	1-12
Y	FR 2 705 677 A (ROQUETTE FRERES) 2 December 1994 cited in the application see abstract see examples see claims	1-12
X	EP 0 665 009 A (NIPPON SHINYAKU COMPANY, LIMITED.) 2 August 1995 cited in the application see abstract see examples see claims	1-12
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

24 February 1997

Date of mailing of the international search report

17. 03. 97

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

Dullaart, A

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J. PHARM. PHARMACOL., VOL. 44, NO. 2, PAGE(S) 73-8, 1992, XP002002172 UEKAMA, KANETO ET AL: "Inhibitory effect of 2- hydroxypropyl -.beta.- cyclodextrin on crystal growth of nifedipine during storage: superior dissolution and oral bioavailability compared with poly(vinylpyrrolidone) K-30" cited in the application * paragraph Materials and methods * see figures ---	1-12
Y	PHARM. WEEKBL. SCI. ED., 1988, VOL. 10, NO. 2, PAGE(S) 80-85, XP002002173 VAN DOORNE H. ET AL: "Formation and antimicrobial activity of complexes of beta- cyclodextrin and some antimycotic imidazole derivatives" cited in the application see abstract * paragraph Results and discussion * see page 85, left-hand column ---	1-12
Y	J. ANTIMICROB. CHEMOTHER., 1993, VOL. 32, NO. 3, PAGE(S) 459-463, XP002002174 HOSTETLER J.S. ET AL: "Effect of hydroxypropyl-beta-cyclodextrin on efficacy of oral itraconazole in disseminated murine cryptococcosis" cited in the application see abstract * paragraph Results *	1-12
Y	JPN. J. MED. MYCOL., 1994, VOL. 35, NO. 3, PAGE(S) 263-267, XP002002175 MIKAMI Y. ET AL: "Effect of carrier solvents on the efficacy of oral itraconazole therapy in aspergillosis in mice" cited in the application see abstract see figures ---	1-12
Y	PHARM. RES., VOL. 11, NO. 12, PAGE(S) 1766-70, 1994, XP002002176 HIRAYAMA, FUMITOSHI ET AL: "Effect of 2- hydroxypropyl -.beta.- cyclodextrin on crystallization and polymorphic transition of nifedipine in solid state" cited in the application see abstract * paragraph Results and discussion * ---	1-12
	-/--	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 009 900 A (LEVINE HARRY ET AL) 23 April 1991 cited in the application see examples see claims -----	1-12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 96/05118

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-7, 11-12
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
In view of the large number of compounds, which are defined by the general definition of the active ingredient used in the claims, the search had to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/210

in the claims, and to the general idea underlying the application
(see Guidelines, chapter III, paragraph 2.3).

Claims searched incompletely: 1-7,11-12

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9411031 A	26-05-94	AU 5376994 A	08-06-94
FR 2705677 A	02-12-94	IT 1265964 B	16-12-96
EP 665009 A	02-08-95	AU 5160793 A	09-05-94
		WO 9408561 A	28-04-94
US 5009900 A	23-04-91	CA 2025647 A	03-04-91